Home/Pipeline/GalNAc Program

GalNAc Program

Alpha-1 Antitrypsin Deficiency (AATD)

PreclinicalActive

Key Facts

Indication

Alpha-1 Antitrypsin Deficiency (AATD)

Phase

Preclinical

Status

Active

Company

Korro Bio

About Korro Bio

Korro Bio is a clinical-stage biotechnology company developing RNA editing therapies via its proprietary OPERA® platform, which co-opts the endogenous ADAR enzyme to make precise adenosine-to-inosine edits. The company has built a diversified pipeline of wholly-owned programs, with its lead candidate, KRRO-121, advancing towards the clinic for hyperammonemia. Korro's strategy leverages validated delivery technologies like GalNAc and LNPs to target high-need indications in the liver and CNS, supported by recent capital raises including an $85 million private placement in March 2026.

View full company profile

Therapeutic Areas

Metabolic & Liver Diseases Neurology

Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs

Drug	Company	Phase	Status
Unnamed AATD Program	AlveoGene	Pre-clinical	Lead Program
NB-101	Nerai Biosciences	Pre-clinical	Active
Undisclosed	GondolaBio	IND Enabling	Active
TSRA-196	Tessera Therapeutics	Phase 1	Active
BEAM-302 (for Beam Therapeutics)	Richmond Pharmacology	Phase 1/2	Active
KB408	Krystal Biotech	Preclinical	Active
Alpha-1 Antitrypsin (AAT)	Grifols	Marketed	Lifecycle Management
BEAM-302	Beam Therapeutics	Phase 1/2	Active